CS Paper Radar

CHIMERA Challenge: Biochemical Recurrence Prediction in Prostate Cancer Patients using multimodal datasets

Robert N. Spaans, Catherine Chia, Tongjie Wang, Adam Kowalewski, Parandzem Khachatryan, Domingos Oliveira, Khrystyna Faryna, Jean-Paul A. van Basten, Geert Litjens, Nadieh Khalili

eess.IV cs.CV ·submitted 2026-08-21 15:23 UTC · v1
benchmark

Abstract

Biochemical recurrence (BCR), defined as any detectable prostate-specific antigen level after prostatectomy with confirmatory elevation, is widely used as a surrogate endpoint and typically assessed using clinical and pathological variables. Currently, no standardized benchmark exists for multimodal prognostic modeling in urological cancers, partly because curating heterogeneous multimodal data remains challenging. We developed the CHIMERA Challenge, a multimodal benchmark integrating preoperative mpMRI, post-prostatectomy histopathology, patient characteristics, and clinician-derived variables from 267 patients across two institutions. The dataset comprises 801 MRI sequences, 13 clinical variables per case, and 942 WSIs. Training (n=95), validation (n=23), and test (n=149) splits were established and hosted on the Grand Challenge platform. Baseline clinical and pathological characteristics did not differ significantly across splits. Models were evaluated on predicting time to BCR using the C-index. Post-challenge analyses tested how each model type performed when clinician-derived variables were withheld or randomized. Unimodal clinical models achieved the highest test C-index of 0.7402 but proved sensitive to the integrity of these variables, with performance collapsing toward chance (C approximately 0.50) when they were randomized. Multimodal models retained near-baseline performance when these variables were withheld (delta C at most 0.04), indicating their ability to recover prognostic signal directly from imaging data. CHIMERA is the first public, standardized multimodal benchmark for prostate cancer prognosis. Although models using only patient characteristics and clinician-derived variables yielded the highest leaderboard performance, multimodal models demonstrated greater robustness in clinically realistic scenarios where complete expert annotation is not guaranteed.

Comment
38 pages, 3 figures, 3 supplementary figures. Preprint submitted to Medical Image Analysis. Challenge results presented at the CHIMERA workshop, MICCAI 2025. Challenge website: https://chimera.grand-challenge.org/chimera/

Closest papers

Nearest neighbours by meaning across the whole index.

CHIMERA Challenge Task 2 and 3: Response Subtypes Classification and Progression Survival Prediction in Bladder Cancer Patients using Multimodal Datasets

eess.IV ·2026-09-08 ·Catherine Chia
benchmark similarity 0.78
Abstract · arXiv admin comment: This version has been removed by arXiv administrators as the submitter did not have the rights to agree to the license …

High-risk non-muscle-invasive bladder cancer (HR-NMIBC) carries substantial risks of recurrence and progression, while current clinical risk stratification remains limited. CHIMERA was established as a multimodal AI challenge to benchmark prediction in HR-NMIBC under standardized evaluation. Task BRS predicts RNA-seq-defined BCG Response Subtypes from histopathology and structured clinicopathological data, whereas Task Progression models time-to-progression using histopathology, structured data, and RNA sequencing. A multimodal dataset of 368 patients was divided into public training and hidden validation and test sets. In total, 159 submissions were made, and 13 top-performing models were selected for benchmarking. The best models achieved a weighted F1 score of 0.73 for Task BRS and a C-index of 0.68 for Task Progression. Post-challenge analyses revealed task-dependent modality contributions, cohort-dependent performance degradation, and sensitivity to missing structured data. In Task BRS, histopathology partly compensated for pathology-derived structured variables, whereas progression models showed greater dependence on complementary inputs. Cross-model error analysis further identified patients that were consistently difficult across different architectures, with T1 substage associated with prediction difficulty. These findings highlight barriers to transportability and the importance of missingness-aware modeling and independent multi-institutional validation. CHIMERA provides a standardized multimodal benchmark for bladder cancer and a framework for studying not only model performance, but also robustness, information sufficiency, and patient-level prediction failure.

0.13

Conditional Diffusion-Based Generation of T2-Weighted Prostate MRI for Clinically Significant Prostate Cancer Classification

cs.CV ·2026-11-01 ·Xavier Rafael-Palou, Alejandro Vergara-Richart, Ignacio Iborra Roncales, Carmen Prieto-de-la-Lastra, Andreu Antolin-Redondo +2 more
similarity 0.62
Abstract

Scarce and unrepresentative training data limit the performance of prostate MRI prediction models. Synthetic T2-weighted (T2W) MRI may augment training data containing clinically significant prostate cancer (csPCa) and transition zone (TZ) lesions. In this retrospective, single-center, ethics-committee-approved study, we developed a conditional generative model for T2W prostate MRI extending MAISI-v2 with csPCa class, zonal, and lesion-mask-guided conditioning, incorporating a relative advantage weighted loss fine-tuned on 1,303 patients (1,654 lesions). Fidelity was assessed by incremental ablation, and downstream utility was evaluated with T2W-based csPCa classifiers across five simulated training-data scenarios, each testing 18 synthetic-data configurations. The proposed model reduced Fréchet inception distance (FID) from 13.28 (pretrained MAISI-v2) to $2.04 \pm 0.06$ internally (PI-CAI: $3.83 \pm 0.51$). Synthetic augmentation significantly increased AUC in all five scenarios (+0.027 to +0.088; adjusted $p = 0.016$--$0.043$), though cross-institutional augmentation of PI-CAI yielded a non-significant gain (+0.013; $p = 0.397$). Overall, our model improved T2W MRI fidelity, and synthetic images improved csPCa classification under simulated data constraints, although benefit did not transfer significantly across institutions.

0.21

CONTEXT-PCa: Evaluating the role of clinical context in MRI-based AI for detecting clinically significant prostate cancer (study protocol)

cs.AI ·2026-11-14 ·Shiqi Huang, Weixi Yi, Shaheer Ullah Saeed, Yipei Wang, Wen Yan +7 more
similarity 0.61
Abstract

The objective of this study is to investigate the role of clinical variables - their breadth, source, and quality - in the development, utility, and generalisability of an AI system for bi-parametric MRI (bpMRI)-based diagnosis of clinically significant prostate cancer (csPCa). Clinical context is added to the published PI-CAI-2B image-only model, whose weights are fixed. The study cohort comprises 6,022 biparametric MRI cases from 4,540 patients at University College London Hospitals NHS Foundation Trust (2019-2024), of which 4,834 cases (3,632 patients) are held out for internal testing. Forty-three clinical variables are drawn from structured health records, clinical letters, MRI reports, and automated image measurements. The primary endpoint is the difference in the area under the receiver operating characteristic curve (AUROC) between the image-context and image-only models on the internal test set. Secondary analyses compare combining strategies, the contribution of individual variables, and performance across subgroups. All models are further tested on five external cohorts from primary diagnosis and population-based screening.

0.16

A cross-modal generative model for incomplete and degraded prostate MRI with multicentre clinical validation

eess.IV cs.AIcs.CV ·2026-08-17 ·Siyuan Ma, Liang He, Mengying Zhu, Yi Chai, Mengyao Lyu +12 more
published similarity 0.61
Abstract

Missing or degraded sequences can limit prostate multiparametric MRI. We developed MSCNet, a sequence-conditioned cross-modal generative framework for reconstructing unavailable contrasts and restoring degraded acquisitions. Across ten completion tasks, task-specific MSCNet achieved mean structural similarity of 0.818 versus 0.798 for the strongest task-matched comparators; matched-capacity analyses showed larger differences in lesion fidelity and boundary preservation. In a blinded 1,000-case reader study, overall image quality met the prespecified non-inferiority criterion for DWI, ADC and T2W completion, but not T1W. In a separate 200-case diagnostic assessment, AUCs for clinically significant cancer were 0.860 with acquired images, 0.841 with MSCNet and 0.797 with baseline-generated images. A locked 186-case three-hospital cohort supported multicentre transportability. These retrospective results support quality-controlled cross-modal reconstruction as an adjunct to acquired prostate MRI.

0.47

ProtoCouncil: Multi-Encoder Anatomical Prototypes for Prostate Cancer Detection in Micro-Ultrasound

cs.CV cs.AIcs.LG ·2026-11-06 ·Mohammad Mahdi Abootorabi, Nooshin Maghsoodi, Armin Saadat, Obed Dzikunu, Zhuoxin Guo +6 more
similarity 0.61
Abstract · 12 pages, 3 figures, Under Review

Purpose: Micro-ultrasound ($μ$US) is a promising modality for prostate cancer (PCa) detection, but identifying suspicious tissue depends heavily on clinical experience. Models trained on sparse, noisy core-level pathology offer little insight into their decisions and can fail under domain shift. Clinical use needs a traceable decision process and a flag for uncertain predictions. Methods: We introduce ProtoCouncil, in which three foundation encoders (MedSAM, DINOv3 and V-JEPA 2.1) learn case-based prototypes at three anatomical levels: whole gland, needle track and gland sectors. Prototypes are projected onto real training-core regions, and label-free fusion keeps every class logit as a bias plus an exact sum of prototype similarity contributions. Encoder disagreement triggers selective prediction. Results: In five-fold patient-level cross-validation (6,588 cores, 693 patients), ProtoCouncil reaches 82.9% AUROC for clinically significant PCa (csPCa, Grade Group $\geq$3), 4.3 points above the best previously published method. In zero-shot evaluation on two external cohorts, ProtoCouncil achieves higher all-cancer and csPCa AUROC than all previous methods. Nearest same-class exemplars match test-core tumor involvement better than random same-class cases. Externally, csPCa accuracy falls from 79% when encoders agree to 27% when two oppose the fused call. Abstaining on disagreement raises balanced accuracy by 7 and 15 points, while retaining 58% and 54% of the cores. Conclusion: ProtoCouncil grounds core-level predictions in exact similarity-based evidence from real, anatomically indexed training cases, which makes its reasoning interpretable. It achieves the highest csPCa AUROC across three cohorts and identifies unreliable predictions through encoder disagreement.

0.30

Improving PI-RADS Prediction and Prostate Cancer Detection from Multiparametric MRI with Anatomical Guidance

cs.CV cs.AI ·2026-11-03 ·Seungbin Park, Thibault Heintz, Rachit Saluja, Francesca Khani, Timothy McClure +3 more
similarity 0.60
Abstract

Accurate prediction of Prostate Imaging Reporting and Data System (PI-RADS) scores from multiparametric MRI (mpMRI) remains challenging, more so than clinically significant prostate cancer (csPCa) detection. Given the importance of lesion location in PI-RADS scoring, we evaluated whether incorporating prostate zonal masks improves PI-RADS prediction and csPCa detection across multiple architectures (3D ResNet-18, ResNet-50, and ViT) using a large-scale internal dataset. Anatomical guidance generally improved performance across architectures, with the best results achieved by ResNet-18 with 2-zone guidance for PI-RADS prediction (QWK = 0.511) and ResNet-50 with 5-zone guidance for csPCa detection (AUC = 0.809). Fine-tuned results on external datasets further demonstrated the benefits of anatomical guidance. Furthermore, models with anatomical guidance improved the utility of model-predicted PI-RADS scores for PI-RADS-based csPCa detection (positive defined as PI-RADS>=3). Combining model-predicted and expert-assigned PI-RADS scores significantly increased the AUC from 0.711 to 0.756 (p < 0.05), suggesting that AI-derived PI-RADS scores may provide complementary information to expert assessment for csPCa detection. Overall, our findings highlight the value of incorporating prostate zonal anatomy into deep learning-based prostate MRI assessment.

0.24

Technically Plausible but Clinically Misleading? Expert Evaluation of Patient-Personalized Synthetic Prostate MRI

eess.IV ·2026-08-17 ·Gabriel Paulo Maglalang Israel, Sol Gedde, Alvaro Fernandez-Quilez
published similarity 0.59
Abstract · To appear in SCAI 2026 proceedings

Magnetic resonance imaging (MRI) is central to prostate cancer assessment, yet its acquisition is costly and time-consuming, making it a major bottleneck in the patient care pathway. Personalized MRI synthesis is a promising direction because it may allow the generation of clinically realistic images tailored to individual patients while reducing the dependence on scanner-acquired imaging. In this work, we in-vestigate whether patient-personalized MRI synthesis produces images that experts perceive as clinically plausible and how such personaliza-tion influences expert interpretation. We synthesize patient-personalized prostate MRI using a 3D diffusion model conditioned on routine pre-imaging clinical variables age and PSA. Using a large publicly available dataset, we first verify that synthesized images are technically compara-ble to scanner-acquired MRIs using standard image similarity metrics. We then conduct a pilot, single-blinded, randomized expert study on a subset of cases sampled to reflect variation in patient clinical pro-files. A radiologist compared personalized and unconditioned synthetic MRIs using paired assessments and Likert-scale ratings of clinical plausibility, confidence, and risk of misleading interpretation, supplemented by qualitative feedback. Although personalized synthetic MRIs appeared technically plausible, expert interpretation highlighted variability in con-fidence and potential risks of misleading cues when routine clinical data was embedded into image generation. These findings suggest that while personalized synthesis may be technically feasible, careful assessment is needed to understand how generated cues influence clinician interpreta-tion before such systems can be safely integrated into clinical workflows.

0.33

ST-Dist: Distilling Spatial Transcriptomics Predictions into Interpretable Gene Axes for Distant Metastasis Prediction

eess.IV ·2026-11-11 ·Sandesh Pokhrel, Hamid Manoochehri, Beatrice S. Knudsen, Tolga Tasdizen
similarity 0.58
Abstract

Distant metastasis at diagnosis determines the treatment of prostate cancer, but predicting it from routine biopsy slides is challenging as the signs of metastasis are not clearly localized and are more subtle than in standard tumor detection and subtyping tasks. Multiple instance learning (MIL) on pathology foundation-model features has become the standard approach when labeled data are abundant, but such models remain hard to interpret. Distant metastasis is further challenging, because confirming the label requires clinical follow-up beyond the routine H&E slides. To this end, we propose ST-Dist, which distills the gene expression predicted by a spatial transcriptomics (ST) model into a linear head mapping each tile's foundation-model features onto named gene axes. The slide's projections along these interpretable gene axes are then used for distant metastasis prediction with a simple logistic regression. On 497 prostate needle biopsies (205 patients), ST-Dist reaches an AUROC of 91.37%, above nine MIL baselines. It remains competitive on the public TCGA-COAD and TCGA-KIRC cohorts, and it has the highest mean AUROC over the three cohorts. The ablations on the prostate biopsies show that the gene axes outperform a linear probe on encoder features, dimension-matched principal components, random gene panels and the ST model's own predicted expression, and the gain over the probe holds on all 13 pathology encoder settings that we tested. ST-Dist thus offers a simple, accurate and interpretable route from H&E to distant metastasis prediction.

0.12